Nowarta110 (Nowarta Biopharma Inc.)

**Nowarta110** is a topical investigational botanical formulation developed by Nowarta Biopharma for plantar warts associated with human papillomavirus infection. Publicly reported composition consists of **colloidal silver and fig extract**. It was evaluated in a randomized, double-blind Phase I/II clinical trial in patients with plantar warts, which is listed as completed. A defined molecular target and validated molecular mechanism have not been publicly established; reported activity includes lesion clearance in plantar-wart patients and cytotoxic or tumor-regression findings in HPV-transformed cell and mouse cancer models. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02338336))

Other names

Nowarta-110Nowarta110Nowarta 110